CA1063048A - Produit oncolytique tire de clostridium perfringens - Google Patents
Produit oncolytique tire de clostridium perfringensInfo
- Publication number
- CA1063048A CA1063048A CA212,447A CA212447A CA1063048A CA 1063048 A CA1063048 A CA 1063048A CA 212447 A CA212447 A CA 212447A CA 1063048 A CA1063048 A CA 1063048A
- Authority
- CA
- Canada
- Prior art keywords
- tumor
- growth
- product
- clostridium perfringens
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 7
- 241000193468 Clostridium perfringens Species 0.000 title claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 230000002238 attenuated effect Effects 0.000 claims abstract description 10
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 230000012010 growth Effects 0.000 claims abstract description 8
- 239000001963 growth medium Substances 0.000 claims abstract description 6
- 239000007362 sporulation medium Substances 0.000 claims abstract description 6
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000004083 survival effect Effects 0.000 claims abstract description 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 241000699670 Mus sp. Species 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229920000298 Cellophane Polymers 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 4
- 241000193403 Clostridium Species 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- HLCHESOMJVGDSJ-UHFFFAOYSA-N thiq Chemical compound C1=CC(Cl)=CC=C1CC(C(=O)N1CCC(CN2N=CN=C2)(CC1)C1CCCCC1)NC(=O)C1NCC2=CC=CC=C2C1 HLCHESOMJVGDSJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA212,447A CA1063048A (fr) | 1974-10-28 | 1974-10-28 | Produit oncolytique tire de clostridium perfringens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA212,447A CA1063048A (fr) | 1974-10-28 | 1974-10-28 | Produit oncolytique tire de clostridium perfringens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1063048A true CA1063048A (fr) | 1979-09-25 |
Family
ID=4101478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA212,447A Expired CA1063048A (fr) | 1974-10-28 | 1974-10-28 | Produit oncolytique tire de clostridium perfringens |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1063048A (fr) |
-
1974
- 1974-10-28 CA CA212,447A patent/CA1063048A/fr not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Griffith | The significance of penumococcal types | |
| CA1246445A (fr) | Agent ameliorant la flore intentinale | |
| EP0018154B1 (fr) | Mutants de Vibrio cholerae, vaccin les comprenant, procédé de préparation d'une de ses sous-unités et composition comprenant celle-ci | |
| CH660375A5 (it) | Procedimento per la produzione di proteine correlate alla tossina difterica. | |
| US3936354A (en) | Anti-tumour product of bacterial origin | |
| CA1135640A (fr) | Substance anti-tumorale et procede de preparation | |
| Takai et al. | Effect of growth temperature on maintenance of virulent Rhodococcus equi | |
| CA1063048A (fr) | Produit oncolytique tire de clostridium perfringens | |
| Perry et al. | Effect of filtrates from transformable and nontransformable streptococci on the transformation of streptococci | |
| US4436725A (en) | Physiologically active novel substance mutastein and process for its production | |
| Delisle | Activity of two Streptococcus mutans bacteriocins in the presence of saliva, levan, and dextran | |
| US3793150A (en) | Equine strangles vaccine and method of preparing and using the same | |
| US4656037A (en) | SPF-100 and process for the preparation thereof | |
| Shattock et al. | Mutants of Phytophthora infestans resistant to, and dependent upon, antibiotics | |
| Ng et al. | Analogy of Mycobacterium marinum disease to Mycobacterium leprae infection in footpads of mice | |
| CA1286623C (fr) | Agent permettant d' ameliorer la fonction hepatique et d'abaisser la tension arterielle | |
| Cowan | The separation of virulent cultures of B. diphtheriae into virulent and avirulent types | |
| Molnar et al. | Selection of lon mutants in Escherichia coli by treatment with phenothiazines | |
| US3843451A (en) | Microorganism production | |
| Turcotte | Yield of non-dialyzable mycobacterial constituents during the growth cycle | |
| SU1658432A1 (ru) | Штамм гриба entomophtora thaxteriana для получения препарата против сосущих насекомых и клещей | |
| Parle | The growth of Saccharomycopsis guttulata | |
| JPS5946597B2 (ja) | 新抗生物質ｓｆ−１１３０−ｘ１物質，その製造法及び免疫賦活剤 | |
| US3699002A (en) | Dextran hydrolizing enzymes | |
| Berk et al. | Properties of Pseudomonas aeruginosa exhibiting self-lysis |